Nventa expands Clinical and Scientific Advisory Board



    SAN DIEGO, CA, Oct. 4 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) today announced the expansion of its recently formed Clinical and
Scientific Advisory Board (CSAB), adding three members with experience
directly relevant to the Company's development programs, including its lead
HspE7 clinical program for human papillomavirus (HPV)-related diseases.
    Strengthening its already robust CSAB, these distinguished advisors add
even more depth in the fields of immunology and clinical research in
HPV-related diseases. The new members include:

    
    -   Mark H. Einstein, MD, MSc: Assistant Professor, Director of Clinical
        Research, Division of Gynecologic Oncology, Department of Obstetrics
        and Gynecology and Women's Health, Albert Einstein College of
        Medicine and Montefiore Medical Center, New York. Dr. Einstein's
        clinical focus is in the development of immunotherapeutics, primarily
        in the area of women's health with a focus on HPV-related lesions.

    -   Warner K. Huh, MD: Assistant Professor, Department of Obstetrics and
        Gynecology, Division of Gynecologic Oncology, University of Alabama,
        Birmingham (UAB) and Associate Scientist, UAB Comprehensive Cancer
        Center. Dr. Huh's expertise is in the development of clinical
        approaches for the treatment of cervical lesions resulting from HPV
        infection.

    -   Richard Ulevitch, PhD: Chairman, Department of Immunology, The
        Scripps Research Institute, San Diego, California. Dr. Ulevitch's
        research is centered on understanding the innate immune system and
        the factors that contribute to the body's identification of pathogens
        and the resulting immune responses.
    

    Commenting on the expansion, Gregory M. McKee, Nventa's President and
Chief Executive Officer stated: "We feel very fortunate to be in a position to
attract such a prestigious group of experts. These additional members
complement our existing team nicely and we expect that they will provide
outstanding guidance as we continue to advance our HspE7 and other programs
forward."

    About Nventa Biopharmaceuticals Corporation:
    --------------------------------------------
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The Company is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa
Biopharmaceuticals Corporation, please visit the Company's website located at
www.nventacorp.com.

    %SEDAR: 00023483E




For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,
dslade@nventacorp.com

Organization Profile

NVENTA BIOPHARMACEUTICALS CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890